Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: An open-label, uncontrolled usability test

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 2906-2914

  Fuchs, Gitte Schøning ^a   Mikkelsen, Søren ^a   Knudsen, Thomas Kamp ^a   Kappelgaard, Anne Marie ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

acceptability; growth hormone deficiency; Norditropin; pediatrics; pen device

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; LEFT HANDEDNESS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; RELIABILITY; RIGHT HANDEDNESS;

ADOLESCENT; CHILD; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS; MALE; MATERIALS TESTING; NEEDLES; PATIENT SATISFACTION; PILOT PROJECTS; QUESTIONNAIRES; RECOMBINANT PROTEINS; SELF ADMINISTRATION;

EID: 74849114982     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.014     Document Type: Article

References (27)

1. Krysiak R., Gdula-Dymek A., Bednarska-Czerwinska A., and Okopien B. Growth hormone therapy in children and adults. Pharmacol Rep. 59 (2007) 500-516
2. Dumas H., Panayiotopoulos P., Parker D., and Pongpairochana V. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord. 6 (2006) 5
3. Jorgensen J.O., Pedersen S.A., Thuesen L., et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1 (1989) 1221-1225
4. Ho K.K., and 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: A statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 157 (2007) 695-700
5. Blethen S.L., Baptista J., Kuntze J., et al., Genentech Growth Study Group. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. J Clin Endocrinol Metab. 82 (1997) 418-420
6. Rappaport R., Mugnier E., Limoni C., et al., French Serono Study Group. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. J Clin Endocrinol Metab. 82 (1997) 452-456
7. Hunter I., de Vries C., Morris A., et al. Human growth hormone therapy: Poor adherence equals poor growth. Arch Dis Child. 82 Suppl 1 (2000) A8 Abstract P28
8. Kapoor R.R., Burke S.A., Sparrow S.E., et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 93 (2008) 147-148
9. Haverkamp F., Johansson L., Dumas H., et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther. 30 (2008) 307-316
10. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society. J Clin Endocrinol Metab. 85 (2000) 3990-3993
11. Bajpai A., and Menon P.S. Growth hormone therapy. Indian J Pediatr. 72 (2005) 139-144
12. Clayton P.E., Cuneo R.C., Juul A., et al., European Society of Paediatric Endocrinology. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 152 (2005) 165-170
13. Schifferdecker E., Schmidt K., Boehm B.O., and Schatz H. Long-term compliance of intensified insulin therapy. Diabetes Res Clin Pract. 23 (1994) 17-23
14. Jorgensen J.T. Improvement of patient convenience in treatment with growth hormone. J Pediatr Endocrinol. 7 (1994) 175-180
15. Chan H. Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. J Adv Nurs. 35 (2001) 882-892
16. Bellary S., and Barnett A.H. Inhaled insulin (Exubera): Combining efficacy and convenience. Diab Vasc Dis Res. 3 (2006) 179-185
17. Drent M.L., Jakobsdottir S., van Wijk J.A., et al. Acceptability of liquid human growth hormone (hGH) [Nor-ditropin SimpleXx] in adults and children with GH deficiency and children with chronic renal disease. Clin Drug Invest. 22 (2002) 633-638
18. Bondy C.A., and Turner Syndrome Study Group. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 92 (2007) 10-25
19. Marchisotti F.G., Carvalho L.R., Berger K., et al. Growth hormone (GH) deficiency treatment in children: Comparison between uses of pen versus bottles/syringes on GH administration [in Portuguese]. Arq Bras Endocrinol Metabol. 51 (2007) 1093-1096
20. Oyarzabal M., Aliaga M., Chueca M., et al. Multicentre survey on compliance with growth hormone therapy: What can be improved?. Acta Paediatr. 87 (1998) 387-391
21. Pfützner A., Reimer T., Hohberg C., et al. Prefilled insulin device with re- duced injection force: Patient perception and accuracy. Curr Med Res Opin. 24 (2008) 2545-2549
22. Western Institutional Review Board. http://www.wirb.com/content/inv_informed_consent.aspx Accessed December 8, 2009
23. Kemp S. Growth Hormone Deficiency. http://emedicine.medscape.com/article/923688-overview Accessed September 14, 2009
24. Couto I., Hansen N.-A., Vang-Petersen M., et al. Injection force dynamics of improved NordiFlex [somatropin (rDNA origin)] versus the current version of Norditropin NordiFlex. J Pediatr Nurs. 24 (2009) 236-237
25. Pfützner A., Reimer T., Hohberg C., et al. Prefilled insulin device with reduced injection force: Patient perception and accuracy. Curr Med Res Opin. 24 (2008) 2545-2549
26. Lytzen L., and Ostfeldt L. Comparative assessment of NovoTwist, a novel insulin pen needle system. Diabetes Care. 58 Suppl 1 (2009) A509 Abstract
27. Kappelgaard A.M., Bojesen A., Skydsgaard K., et al. Liquid growth hormone: Preservatives and buffers. Horm Res. 62 Suppl 3 (2004) 98-103